The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)

Launched by JASPER GERRITSEN · Nov 18, 2023

Keywords

ClinConnect Summary

The RESBIOP study is researching the best surgical approach for older patients (70 years and older) or those with limited health status who are diagnosed with high-grade gliomas, a type of aggressive brain tumor. The main goal is to compare two methods: removing as much of the tumor as possible (resection) versus taking a small sample of the tumor (biopsy). By looking at how these methods affect survival, quality of life, and the chance of receiving additional treatments like chemotherapy or radiation, the study hopes to provide clearer guidance for doctors and patients.

To participate in this study, individuals must be between 18 and 90 years old and have been diagnosed with a high-grade glioma based on MRI scans. Participants will be randomly assigned to either the resection or biopsy group and will be followed for one year after their procedure. Throughout the study, researchers will monitor participants’ health, quality of life, and any side effects experienced. This study is currently recruiting participants and will last a total of five years.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥18 years and ≤90 years
• • 2. Tumor diagnosed as HGG (WHO grade III/IV) on MRI as assessed by the neurosurgeon
• • 3. Written informed consent
• Exclusion Criteria:
• • 1. Tumors of the cerebellum, brainstem or midline
• • 2. Medical reasons precluding MRI (e.g. pacemaker)
• • 3. Inability to give written informed consent
• • 4. Secondary high-grade glioma due to malignant transformation from low-grade glioma
• • 5. Second primary malignancy within the past 5 years with the exception of adequately treated in situ carcinoma of any organ or basal cell carcinoma of the skin